



# Agilent

Trusted Answers



## PD-L1 IHC 22C3 pharmDx in TNBC

### Your Report. A Patient's Future.

In triple-negative breast cancer (TNBC), PD-L1 IHC 22C3 pharmDx (SK006) is the only PD-L1 companion diagnostic assay approved by the FDA to identify patients for treatment with KEYTRUDA® (pembrolizumab).

For training in TNBC Combined Positive Score (CPS) contact: [pathology.solutions@agilent.com](mailto:pathology.solutions@agilent.com)



KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. For countries outside of the United States, see the local KEYTRUDA product label for approved prescription information to guide therapy. Refer to the PD-L1 IHC 22C3 pharmDx instructions for use for more information.

This information is subject to change without notice.

© Agilent Technologies, Inc. 2021